EHA 2017 | Is gilteritinib the new breakthrough in the treatment of FLT3-mutated AML?
Mark Levis, MD, PhD, from John Hopkins University, Baltimore, MD, USA, presents us with an insight on how gilteritinib, a next-generation FLT3 inhibitor, is superior over previous FLT3 inhibitors in treating FLT3-mutated acute myeloid leukemia (AML). He also details the difficulty in quantifying responses from patients with relapsed FLT3-mutated AML who have been treated with a single agent, but adds that his team have developed an assay using next-generation sequencing that has allowed them to overcome these issues. He concludes with a statement on the recent retrieval of Phase I/II trial data (NCT02014558) focused on the study of gilteritinib in treating FLT-mutated AML and adds that the drug is now undergoing Phase III trials. This interview was filmed at the European Hematology Association (EHA) 2017 Annual Congress in Madrid, Spain.
Get great new content delivered to your inboxSign up